Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Refractory GERD and SIBO: Clinical Features and Mechanistic Links
ChiCTR2500112032Phase 4Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rifaximin in gastroesophageal reflux disease (GERD) and blind loop syndrome (BLS), sponsored by Peking University Third Hospital. Primary endpoint: Treatment response rate (RDQ score reduction ≥50%). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
rifaximin
03
Conditions
gastroesophageal reflux disease (GERD)blind loop syndrome (BLS)
Beyond the preview
Go deeper on ChiCTR2500112032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112032.